Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA) General Counsel Iqbal J. Hussain Sells 6,000 Shares

Key Points

• General Counsel Iqbal J. Hussain sold 6,000 shares of Centessa Pharmaceuticals at an average price of $17.23, reducing his ownership by 5.39% and retaining 105,386 shares valued at approximately $1.82 million.
• Centessa Pharmaceuticals' stock price increased by 2.3% during trading, reaching $18.05 with a notable trading volume of 1.28 million shares.
• Multiple analysts provided positive outlooks for the company's stock, with price targets ranging from $6.00 to $35.00, resulting in an average rating of "Moderate Buy".

Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA - Get Free Report) General Counsel Iqbal J. Hussain sold 6,000 shares of the company's stock in a transaction that occurred on Friday, August 15th. The stock was sold at an average price of $17.23, for a total value of $103,380.00. Following the transaction, the general counsel directly owned 105,386 shares in the company, valued at $1,815,800.78. The trade was a 5.39% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.

Centessa Pharmaceuticals Stock Up 2.3%

Shares of Centessa Pharmaceuticals stock traded up $0.41 during trading on Friday, reaching $18.05. The company's stock had a trading volume of 1,282,676 shares, compared to its average volume of 965,058. The company has a quick ratio of 14.37, a current ratio of 10.11 and a debt-to-equity ratio of 0.32. The company has a market cap of $2.42 billion, a price-to-earnings ratio of -10.08 and a beta of 1.48. Centessa Pharmaceuticals PLC Sponsored ADR has a 1-year low of $9.60 and a 1-year high of $19.09. The company has a 50-day simple moving average of $14.64 and a two-hundred day simple moving average of $14.50.

Centessa Pharmaceuticals (NASDAQ:CNTA - Get Free Report) last issued its quarterly earnings results on Tuesday, August 12th. The company reported ($0.38) EPS for the quarter, missing analysts' consensus estimates of ($0.35) by ($0.03). As a group, equities analysts forecast that Centessa Pharmaceuticals PLC Sponsored ADR will post -1.6 earnings per share for the current year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the stock. GF Fund Management CO. LTD. purchased a new position in shares of Centessa Pharmaceuticals during the fourth quarter worth $31,000. Caitong International Asset Management Co. Ltd lifted its holdings in shares of Centessa Pharmaceuticals by 15,209.5% in the 1st quarter. Caitong International Asset Management Co. Ltd now owns 3,215 shares of the company's stock valued at $46,000 after purchasing an additional 3,194 shares during the last quarter. Osterweis Capital Management Inc. acquired a new position in Centessa Pharmaceuticals in the 1st quarter valued at about $47,000. Barclays PLC increased its position in Centessa Pharmaceuticals by 1,414.9% during the 4th quarter. Barclays PLC now owns 5,302 shares of the company's stock worth $89,000 after purchasing an additional 4,952 shares during the period. Finally, Bank of New York Mellon Corp acquired a new stake in shares of Centessa Pharmaceuticals in the 1st quarter worth approximately $147,000. 82.01% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of brokerages have issued reports on CNTA. Chardan Capital restated a "buy" rating and issued a $30.00 price objective on shares of Centessa Pharmaceuticals in a research note on Tuesday. Wall Street Zen upgraded Centessa Pharmaceuticals from a "sell" rating to a "hold" rating in a research note on Thursday, May 22nd. Oppenheimer initiated coverage on Centessa Pharmaceuticals in a research note on Thursday, May 8th. They set an "outperform" rating and a $6.00 price target for the company. Needham & Company LLC initiated coverage on Centessa Pharmaceuticals in a report on Wednesday, May 28th. They set a "buy" rating and a $35.00 price objective on the stock. Finally, Truist Financial initiated coverage on Centessa Pharmaceuticals in a report on Monday, July 21st. They set a "buy" rating and a $30.00 price objective on the stock. One investment analyst has rated the stock with a hold rating and eleven have given a buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average price target of $28.10.

Centessa Pharmaceuticals Company Profile

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.